Lataa...
AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials
Epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) constitute the standard of care for stage IV EGFR mutated non-small cell lung cancer (NSCLC) patients initiating first-line systemic treatment. Despite the initial remarkable activity of targeted treatment in these patients re...
Tallennettuna:
| Julkaisussa: | Transl Lung Cancer Res |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
AME Publishing Company
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4758983/ https://ncbi.nlm.nih.gov/pubmed/26958497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.02 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|